SCHEMBL264604

SCHEMBL264604

COc1cc(Cl)c(Cl)c(-c2ccc(NC(=O)c3ccnn3C)nc2N)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 13/20 0.81
SCN9A Q15858 3/20 0.81
SCN1A P35498 2/20 0.81
SCN5A Q14524 2/20 0.81
SCN2A Q99250 2/20 0.50
SCN3A Q9NY46 2/20 0.50
HTT P42858 2/20 0.48
NPC1 O15118 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
RAB9A P51151 1/20 0.45
KCNH2 Q12809 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MAP4K1 Q92918 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pf-04531083 SCHEMBL29387055 0.89 SCN10A (1.00) SCN10ASCN9ASCN1ASCN5ASCN2A
Pf-04531083 SCHEMBL261689 0.89 SCN10A (1.00) SCN10ASCN9ASCN1ASCN5ASCN2A
SCHEMBL14237595 0.89 SCN10A (0.64) SCN10ASCN9ASCN1ASCN5ASCN2A
SCHEMBL261982 0.88 SCN10A (1.00) SCN10ASCN9ASCN1ASCN5ASCN2A
SCHEMBL14237398 0.87 SCN10A (0.83) SCN10ASCN9ASCN1ASCN5ASCN2A
SCHEMBL14237556 0.86 SCN10A (0.61) SCN10ASCN9ASCN1ASCN5ASCN2A
SCHEMBL2413827 0.86 SCN10A (0.63) SCN10ASCN9ASCN1ASCN5AHTT
SCHEMBL263363 0.85 SCN10A (0.81) SCN10ASCN9ASCN1ASCN5ASCN2A
SCHEMBL14237460 0.83 SCN10A (0.84) SCN10ASCN9ASCN1ASCN5ASCN2A
SCHEMBL263764 0.82 SCN10A (0.86) SCN10ASCN9ASCN1ASCN5ASCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP claimed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US claimed
JP-4657384-B2 2011-03-23 JP claimed
JP-2010526050-A 2010-07-29 JP claimed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP claimed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US claimed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO claimed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 SCN10A 358/4885SCN9A 491/4885SCN1A 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.